Stuart W. Peltz
Net Worth
Last updated:
What is Stuart W. Peltz net worth?
The estimated net worth of Dr. Stuart W. Peltz is at least $45,600,062 as of 31 Jan 2023. He owns shares worth $2,696,286 as insider, has earned $24,203,776 from insider trading and has received compensation worth at least $18,700,000 in PTC Therapeutics, Inc..
What is the salary of Stuart W. Peltz?
Dr. Stuart W. Peltz salary is $1,700,000 per year as Co-Founder, Chief Executive Officer & Executive Director in PTC Therapeutics, Inc..
How old is Stuart W. Peltz?
Dr. Stuart W. Peltz is 65 years old, born in 1960.
What stocks does Stuart W. Peltz currently own?
As insider, Dr. Stuart W. Peltz owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| PTC Therapeutics, Inc. (PTCT) | Co-Founder, Chief Executive Officer & Executive Director | 54,903 | $49.11 | $2,696,286 |
What does PTC Therapeutics, Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Stuart W. Peltz insider trading
PTC Therapeutics, Inc.
Dr. Stuart W. Peltz has made 45 insider trades between 2014-2023, according to the Form 4 filled with the SEC. Most recently he sold 301 units of PTCT stock worth $13,734 on 31 Jan 2023.
The largest trade he's ever made was exercising 368,434 units of PTCT stock on 7 Dec 2020. As of 31 Jan 2023 he still owns at least 54,903 units of PTCT stock.
PTC Therapeutics key executives
PTC Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Allan Steven Jacobson (79) Independent Co-Founder, Chairman of Scientific Advisory Board & Director
- Dr. Neil Almstead (58) Chief Technical Operations Officer
- Dr. Stuart W. Peltz (65) Co-Founder, Chief Executive Officer & Executive Director
- Mr. Eric Pauwels (63) Chief Bus. Officer
- Mr. Mark Elliott Boulding (64) Executive Vice President & Chief Legal Officer
- Ms. Emily Luisa Hill (44) Chief Financial Officer